SB 317 — Opioid Terminology Amendments

(i) the known, or discoverable on reasonable inquiry, causes and contributing factors of each of the in-custodyin- custody deaths described in Subsection (2)(g);

- 6 - SB0317 compared with SB0317S01 (ii) that relate to the county jail's provision, or lack of provision, of medications used to treat, mitigate, or address a prisoner's symptoms of withdrawal, including methadone and all forms of buprenorphine and naltrexone;

(l)(i)(l) (i) the number of prisoners whose screening described in Section 17-72-501 indicated the presence of a substance use disorder;

(2)(a)(2) (a) Subsection (1) does not apply to a county jail if the county jail:

-(i) 6collects -and 03-03stores 19:10the 1stdata Sub.described in Subsection (1);

(Green) S.B.

317 (i) collects and stores the data described in Subsection (1);

and (ii)(A)(ii) (A) the county jail approves the report for release;

or - 7 - SB0317 compared with SB0317S01 (C) the county jail fails to provide a response to the report within four weeks after the day on which the commission provides the report to the county jail.

26B-4-50126B-4-501. (Effective 05/06/26).

-(1) 7"Controlled -substance" 1stmeans Sub.the same as that term is defined in Title 58, Chapter 37, Utah Controlled Substances Act.

(Green) S.B.

317 03-03 19:10 (1) "Controlled substance" means the same as that term is defined in Title 58, Chapter 37, Utah Controlled Substances Act.

- 8 - SB0317 compared with SB0317S01 (8) "General acute hospital" means the same as that term is defined in Section 26B-2-201.

-(14) 8"[Opiate-related] -Opioid-related 03-03drug 19:10overdose 1stevent" Sub.means an acute condition, including a decreased level of consciousness or respiratory depression resulting from the consumption or use of a controlled substance, or another substance with which a controlled substance was combined, and that a person would reasonably believe to require medical assistance.

(Green) S.B.

317 (14) "[Opiate-related] Opioid-related drug overdose event" means an acute condition, including a decreased level of consciousness or respiratory depression resulting from the consumption or use of a controlled substance, or another substance with which a controlled substance was combined, and that a person would reasonably believe to require medical assistance.

- 9 - SB0317 compared with SB0317S01 (h) an organization providing substance use or mental health services under contract with a local substance abuse authority, as defined in Section 26B-5-101, or a local mental health authority, as defined in Section 26B-5-101;

(22)(a)(22) (a) "Self-administered hormonal contraceptive" means a self-administered hormonal contraceptive that is approved by the United States Food and Drug Administration to -prevent 9pregnancy. - 1st Sub.

(Green) S.B.

317 03-03 19:10 prevent pregnancy.

(23)(a)(23) (a) "Sexual assault" means any criminal conduct described in Title 76, Chapter 5, Part 4, Sexual Offenses, that may result in a pregnancy.

- 10 - SB0317 compared with SB0317S01 (iii) Section 76-5-419, lewdness;

26B-4-50826B-4-508. (Effective 05/06/26).

The following section is affected by a coordination clause at the end of this bill.

26B-4-50926B-4-509. (Effective 05/06/26).

(1)(a)(i)(1) (a) (i) For purposes of Subsection (1)(a)(ii), "a person other than a health care facility or health care provider" includes the following, regardless of whether the person has received funds from the department through the [Opiate][Opiate]Opioid Opioid Overdose Outreach Pilot Program created in Section 26B-4-512:

or (B) an organization, defined by department rule made under Subsection 26B-4-512(7)(e), that is in a position to assist an individual who is at increased risk of experiencing an [opiate-related][opiate- opioid-relatedrelated]opioid-related drug overdose event.

(ii) Except as provided in Subsection (1)(b), the following persons are not liable for any civil damages for acts or omissions made as a result of administering an [[opiate]opioid opiate] opioid antagonist when the person acts in good faith to administer the [[opiate]opioid -antagonist 10to -an 03-03individual 19:10whom 1stthe Sub.person believes to be experiencing an [opiate-related]opioid-related drug overdose event:

(Green) S.B.

317 opiate] opioid antagonist to an individual whom the person believes to be experiencing an [opiate-related] opioid-related drug overdose event:

and - 11 - SB0317 compared with SB0317S01 (ii) is immune from liability under Subsection (1)(a) if the health care provider is under no legal duty to respond and otherwise complies with Subsection (1)(a).

(2) Notwithstanding Sections 58-1-501, 58-17b-501, and 58-17b-502, a health care provider who is licensed to prescribe an [opiate][opiate]opioid opioid antagonist may prescribe, including by a standing prescription drug order issued in accordance with Subsection 26B-4-510(2), or dispense an [opiate][opiate]opioid opioid antagonist:

(a)(i)(a) (i) to an individual who is at increased risk of experiencing an [opiate-related][opiate-related]opioid-related opioid-related drug overdose event;

(A) furnishing the [opiate][opiate]opioid opioid antagonist to an individual described in Subsection (2)(a)(i) or (ii), as provided in Section 26B-4-511;

or (B) administering to an individual experiencing an [opiate-related][opiate-related]opioid-related opioid-related drug overdose event;

and (c) without liability for any civil damages for acts or omissions made as a result of prescribing or dispensing the [opiate][opiate]opioid opioid antagonist in good faith.

(3)(a) Arecognize health care provider who dispenses an [opiate][opiate-related]opioid-related opioiddrug antagonist to an individual or an overdose outreachevent; provider under Subsection (2)(a) shall provide education to the individual or overdose outreach provider that includes written instruction on how to:

(a)and recognize(b) anrespond [opiate-related]appropriately opioid-relatedto an [opiate-related]opioid-related drug overdose event;event, including how to:

and(i) (b)administer respond appropriately to an [opiate-related][opiate]opioid opioid-relatedantagonist; drug overdose event, including how to:

(i)and administer(ii) ensure that an [opiate]individual opioidto antagonist;whom an [opiate]opioid antagonist has been administered receives, as soon as possible, additional medical care and a medical evaluation.

and - 11 - 1st Sub.

(Green) S.B.

317 03-03 19:10 (ii) ensure that an individual to whom an [opiate] opioid antagonist has been administered receives, as soon as possible, additional medical care and a medical evaluation.

The following section is affected by a coordination clause at the end of this bill.

26B-4-51026B-4-510. (Effective 05/06/26).

and - 12 - SB0317 compared with SB0317S01 (b) without any other prescription drug order from a person licensed to prescribe an [[opiate] opiate] opioid antagonist.

(A) furnishing to an individual who is at increased risk of experiencing an [[opiate-related] opiate-related]opioid- opioid-relatedrelated drug overdose event, or to a family member of, friend of, or other individual who is in a position to assist an individual who is at increased risk of experiencing an [opiate-related] opioid-relatedopioid- related drug overdose event, as provided in Section 26B-4-511;

-(b) 12requires -the 03-03physician 19:10to 1stspecify Sub.the persons, by professional license number, authorized to dispense the [opiate] opioid antagonist;

(Green) S.B.

317 (b) requires the physician to specify the persons, by professional license number, authorized to dispense the [opiate] opioid antagonist;

and - 13 - SB0317 compared with SB0317S01 (e) is approved by the Division of Professional Licensing within the Department of Commerce by administrative rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act.

The following section is affected by a coordination clause at the end of this bill.

26B-4-51126B-4-511. (Effective 05/06/26).

(i)(A)(i) (A) to an individual who is at increased risk of experiencing an [opiate-related] opioid-related drug overdose event;

-(i) 13the -written 1stinstruction Sub.under Subsection [26B-4-504(3)] 26B-4-509(3) received by the overdose outreach provider from the health care provider at the time the [opiate] opioid antagonist was dispensed to the overdose outreach provider;

(Green) S.B.

317 03-03 19:10 (i) the written instruction under Subsection [26B-4-504(3)] 26B-4-509(3) received by the overdose outreach provider from the health care provider at the time the [opiate] opioid antagonist was dispensed to the overdose outreach provider;

and (b) may provide additional instruction on how to recognize and respond appropriately to an [opiate-related][opiate- related] opioid-related drug overdose event.

- 14 - SB0317 compared with SB0317S01 Section 8.

26B-4-51226B-4-512. (Effective 05/06/26).

(E) an organization that provides training on the proper administration of an [[opiate] opiate] opioid antagonist in response to an [opiate-related] opioid-related drug overdose event;

-(i) 14a -public 03-03school: 19:10 1st Sub.

(Green) S.B.

317 (i) a public school:

- 15 - SB0317 compared with SB0317S01 (a) provide grants under Subsection (4);

or (ii) pay for the grantee's cost of providing training on the proper administration of an [[opiate] opiate] opioid antagonist in response to an [opiate-related] opioid-related drug -overdose 15event; - 1st Sub.

(Green) S.B.

317 03-03 19:10 overdose event;

- 16 - SB0317 compared with SB0317S01 (b) the criteria used by the department to determine whether a grant request is approved, including criteria providing that:

-26B-4-513. 16 - 03-03 19:10 1st Sub.

(Green) S.B.

317 26B-4-513 (Effective 05/06/26).

26B-4-514- (Effective17 05/06/26).- SB0317 compared with SB0317S01 26B-4-514.

26B-7-11026B-7-110. (Effective 05/06/26).

(1) As used in this section, "[opiate] opioid-like substance" means any drug or other substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or -addiction-sustaining 17liability. - 1st Sub.

(Green) S.B.

317 03-03 19:10 addiction-sustaining liability.

(b) study the risks, warning signs, and solutions to the risks associated with prescription [[opiate] opiate]opioid- opioid-likelike substance medications for chronic pain, including risks and prevention of misuse and diversion of those medications;

- 18 - SB0317 compared with SB0317S01 (c) provide education to health care providers, patients, insurers, and the general public on the appropriate management of chronic pain, including the effective use of medical treatment and quality care guidelines that are scientifically based and peer reviewed;

26B-7-11726B-7-117. (Effective 05/06/26).

-(2) 18An -entity 03-03operating 19:10a 1stsyringe Sub.exchange program in the state shall:

(Green) S.B.

317 (2) An entity operating a syringe exchange program in the state shall:

- 19 - SB0317 compared with SB0317S01 (i) the number of individuals who have exchanged syringes;

-(5) 19An -entity 1stoperating Sub.a syringe exchange program may not facilitate the exchange of syringes at a homeless shelter, as that term is defined in Section 35A-16-501, or permanent supportive housing.

(Green)(6) S.B.(a) The use of state funds to operate a syringe exchange program is prohibited.

317 03-03 19:10 (5) An entity operating a syringe exchange program may not facilitate the exchange of syringes at a homeless shelter, as that term is defined in Section 35A-16-501, or permanent supportive housing.

(6)(a) The use of state funds to operate a syringe exchange program is prohibited.

53G-9-50253G-9-502. (Effective 05/06/26).

(1) A public or private school that holds any classes in grades kindergarten through 12 may provide for the administration of medication, including epinephrine nasal spray as that term is defined - 20 - SB0317 compared with SB0317S01 in Section 26B-4-401, to any student during periods when the student is under the control of the school, subject to the following conditions:

(3) School personnel who provide assistance under Subsection (1) in substantial compliance -with 20the -licensed 03-03health 19:10care 1stprovider's Sub.written prescription and the employers of these school personnel are not liable, civilly or criminally, for:

(Green) S.B.

317 with the licensed health care provider's written prescription and the employers of these school personnel are not liable, civilly or criminally, for:

58-17b-309- (Effective21 05/06/26).- SB0317 compared with SB0317S01 58-17b-309.

The following section is affected by a coordination clause at the end of this bill.

58-17b-50758-17b-507. (Effective 05/06/26).

(a) "[Opiate ] Opioid antagonist" means the same as that term is defined in Section -26B-4-501. 21 - 1st Sub.

(Green) S.B.

317 03-03 19:10 26B-4-501.

(2) A person licensed under this chapter that dispenses an [opiate] opioid antagonist to an individual with a prescription for an [opiate] opioid antagonist, to an overdose outreach provider with a prescription for an [opiate] opioid antagonist, or pursuant to a standing prescription drug order issued in accordance with Subsection 26B-4-510(2) is not liable for any civil damages resulting from the outcomes of the eventual administration of the [[opiate] opiate] opioid antagonist to an individual who another individual believes is experiencing an [opiate-related] opioid-related drug overdose event.

- 22 - SB0317 compared with SB0317S01 (4) It is not unprofessional conduct or unlawful conduct for a licensee under this chapter to dispense an [opiate] opioid antagonist to a person, including a person described in Subsections 26B-4-512(1)(a)(i)(A)26B-4-512(1) (a)(i)(A) through (1)(a)(i)(F), on behalf of an individual if the person obtaining the [opiate] opioid antagonist has a prescription for the [opiate] opioid antagonist from a licensed prescriber or the [opiate] opioid antagonist is dispensed pursuant to a standing prescription drug order issued in accordance with Subsection 26B-4-510(2).

The following section is affected by a coordination clause at the end of this bill.

58-31b-70358-31b-703. (Effective 05/06/26).

(d) "[Opiate-related] Opioid-related drug overdose event" means the same as that term is -defined 22in -Section 03-0326B-4-501. 19:10 1st Sub.

(Green) S.B.

317 defined in Section 26B-4-501.

- 23 - SB0317 compared with SB0317S01 (3) The provisions of this section and Title 26B, Chapter 4, Part 5, Treatment Access, do not establish a duty or standard of care in the prescribing, dispensing, or administration of an [opiate] opioid antagonist.

58-37-258-37-2. (Effective 05/06/26).

(d) "Continuing criminal enterprise" means any individual, sole proprietorship, partnership, corporation, business trust, association, or other legal entity, and any -union 23or -groups 1stof Sub.individuals associated in fact although not a legal entity, and includes illicit as well as licit entities created or maintained for the purpose of engaging in conduct which constitutes the commission of episodes of activity made unlawful by this chapter, Chapter 37a, Utah Drug Paraphernalia Act, Chapter 37b, Imitation Controlled Substances Act, Chapter 37c, Utah Controlled Substance Precursor Act, or Chapter 37d, Clandestine Drug Lab Act, which episodes are not isolated, but have the same or similar purposes, results, participants, victims, methods of commission, or otherwise are interrelated by distinguishing characteristics.

(Green) S.B.

317 03-03 19:10 union or groups of individuals associated in fact although not a legal entity, and includes illicit as well as licit entities created or maintained for the purpose of engaging in conduct which constitutes the commission of episodes of activity made unlawful by this chapter, Chapter 37a, Utah Drug Paraphernalia Act, Chapter 37b, Imitation Controlled Substances Act, Chapter 37c, Utah Controlled Substance Precursor Act, or Chapter 37d, Clandestine Drug Lab Act, which episodes are not isolated, but have the same or similar purposes, results, participants, victims, methods of commission, or otherwise are interrelated by distinguishing characteristics.

(f)(i)(f) (i) "Controlled substance" means a drug or substance:

- 24 - SB0317 compared with SB0317S01 (B) included in Schedules I, II, III, IV, or V of the federal Controlled Substances Act, Title II, P.L.

(g)(i)(g) (i) "Controlled substance analog" means:

(A) a substance the chemical structure of which is substantially similar to the -chemical 24structure -of 03-03a 19:10controlled 1stsubstance Sub.listed in Schedules I and II of Section 58-37-4, a substance listed in Section 58-37-4.2, or in Schedules I and II of the federal Controlled Substances Act, Title II, P.L.

(Green) S.B.

317 chemical structure of a controlled substance listed in Schedules I and II of Section 58-37-4, a substance listed in Section 58-37-4.2, or in Schedules I and II of the federal Controlled Substances Act, Title II, P.L.

or (C) [A] a substance that, with respect to a particular individual, is represented or intended to have a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of controlled substances listed in Schedules I and II of Section 58-37-4, substances listed - 25 - SB0317 compared with SB0317S01 in Section 58-37-4.2, or substances listed in Schedules I and II of the federal Controlled Substances Act, Title II, P.L.

(E) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals, which contains ephedrine, pseudoephedrine, norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold, transferred, or furnished as an over-the-counterover- the-counter medication without prescription;

or (F) dietary supplements, vitamins, minerals, herbs, or other similar substances including concentrates or extracts, which are not otherwise regulated by law, which may contain naturally occurring amounts of chemical or substances -listed 25in -this 1stchapter, Sub.or in rules adopted pursuant to Title 63G, Chapter 3, Utah Administrative Rulemaking Act.

(Green)(h) S.B.(i) "Conviction" means a determination of guilt by verdict, whether jury or bench, or plea, whether guilty or no contest, for any offense proscribed by:

317 03-03 19:10 listed in this chapter, or in rules adopted pursuant to Title 63G, Chapter 3, Utah Administrative Rulemaking Act.

(h)(i) "Conviction" means a determination of guilt by verdict, whether jury or bench, or plea, whether guilty or no contest, for any offense proscribed by:

- 26 - SB0317 compared with SB0317S01 (D) Chapter 37c, Utah Controlled Substance Precursor Act;

-(k) 26"Department" -means 03-03the 19:10Department 1stof Sub.Commerce.

(Green) S.B.

317 (k) "Department" means the Department of Commerce.

- 27 - SB0317 compared with SB0317S01 (m) "Dispense" means the delivery of a controlled substance by a pharmacist to an ultimate user pursuant to the lawful order or prescription of a practitioner, and includes distributing to, leaving with, giving away, or disposing of that substance as well as the packaging, labeling, or compounding necessary to prepare the substance for delivery.

(r)(i)(r) (i) "Drug" means:

(B) a substance that is required by any applicable federal or state law or rule to be -dispensed 27by -prescription 1stonly Sub.or is restricted to administration by practitioners only;

(Green) S.B.

317 03-03 19:10 dispensed by prescription only or is restricted to administration by practitioners only;

and (D) substances intended for use as a component of any substance specified in Subsections (1)(r)(i)(A),(1)(r)(i) (A), (B), and (C).

(t)(i)(t) (i) "Food" means:

- 28 - SB0317 compared with SB0317S01 (A) any nutrient or substance of plant, mineral, or animal origin other than a drug as specified in this chapter, and normally ingested by human beings;

(i) the origin and interpretation of which is from within a traditional Indian culture or -community; 28 - 03-03 19:10 1st Sub.

(Green) S.B.

317 community;

(aa)(i)(aa) - 29 - SB0317 compared with SB0317S01 (i) "Marijuana" means all species of the genus cannabis and all parts of the genus, whether growing or not, including:

-(F) 29any -compound, 1stmixture, Sub.or preparation approved by the federal Food and Drug Administration under the federal Food, Drug, and Cosmetic Act, 21 U.S.C.

(Green) S.B.

317 03-03 19:10 (F) any compound, mixture, or preparation approved by the federal Food and Drug Administration under the federal Food, Drug, and Cosmetic Act, 21 U.S.C.

(ii) a compound, manufacture, salt, derivative, or preparation of opium, coca leaves, or [opiates] opioid-likeopioid- like substances;

or - 30 - SB0317 compared with SB0317S01 (iv) a substance, and any compound, manufacture, salt, derivative, or preparation of the substance, which is chemically identical with any of the substances referred to in Subsection (1)(cc)(i), (ii), or (iii), except narcotic drug does not include decocainized coca leaves or extracts of coca leaves which do not contain cocaine or ecgonine.

(ii) "Possession" or "use" means the joint or individual ownership, control, occupancy, -holding, 30retaining, -belonging, 03-03maintaining, 19:10or 1stthe Sub.application, inhalation, swallowing, injection, or consumption, as distinguished from distribution, of controlled substances and includes individual, joint, or group possession or use of controlled substances.

(Green) S.B.

317 holding, retaining, belonging, maintaining, or the application, inhalation, swallowing, injection, or consumption, as distinguished from distribution, of controlled substances and includes individual, joint, or group possession or use of controlled substances.

or - 31 - SB0317 compared with SB0317S01 (ii) by telephone, facsimile transmission, computer, or other electronic means of communication as defined by division rule.

(2) If a term used in this chapter is not defined, the definition and terms of Title 76, Utah -Criminal 31Code, -shall 1stapply. Sub.

(Green) S.B.

317 03-03 19:10 Criminal Code, shall apply.

58-37-458-37-4. (Effective 05/06/26).

- 32 - SB0317 compared with SB0317S01 (E) Allylprodine;

1-(1-methyl-2-phenylethyl)-4-(N-propanilido)1-(1- methyl-2-phenylethyl)-4-(N-propanilido) piperidine);

N-[1-(2-hydroxy-2- phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;phenethyl)-3-methyl-4- piperidinyl]-N-phenylpropanamide;

-(P) 32Betameprodine; - 03-03 19:10 1st Sub.

(Green) S.B.

317 (P) Betameprodine;

- 33 - SB0317 compared with SB0317S01 (GG) Etonitazene;

-(TT) 33Normethadone; - 1st Sub.

(Green) S.B.

317 03-03 19:10 (TT) Normethadone;

(WW) Para-fluoroisobutyryl fentanyl (N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);(N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4- yl)isobutyramide);

(III) Tetrahydrofuran fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);(N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2- carboxamide);

- 34 - SB0317 compared with SB0317S01 (JJJ) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;

(NNN) 3-methylfentanyl, including the optical and geometric isomers (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-(N-[3-methyl-1-(2- phenylethyl)-4-piperidyl]- N-phenylpropanamide);

-(A) 34Acetorphine; - 03-03 19:10 1st Sub.

(Green) S.B.

317 (A) Acetorphine;

- 35 - SB0317 compared with SB0317S01 (T) Nicomorphine;

as used in this Subsection (2)(a)(iii)(2) (a)(iii) only, "isomer" includes the optical, position, and geometric isomers:

αα-ethyl-1H-indole-3- -ethyl-1H-indole-3-ethanamine;ethanamine;

4-bromo-2,5-dimethoxy-α-methylphenethylamine;4-bromo-2,5-dimethoxy-α- methylphenethylamine;

-2-(4-bromo-2,5- 35dimethoxyphenyl)-1-aminoethane; - 1st Sub.

(Green) S.B.

317 03-03 19:10 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane;

2,5-dimethoxy-α2,5-dimethoxy-α-methylphenethylamine; -methylphenethylamine;

4-methoxy-α4-methoxy-α-methylphenethylamine; -methylphenethylamine;

4-methyl-2,5-dimethoxy-α-methylphenethylamine;4-methyl-2,5-dimethoxy-α- methylphenethylamine;

(K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl- alpha-methyl-3,4(methylenedioxy)phenethylamine,alpha- methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;

(L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine,N-hydroxy-alpha- methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;

- 36 - SB0317 compared with SB0317S01 (N) Bufotenine, some trade and other names:

3-(β3-(β-Dimethylaminoethyl)-5-hydroxyindole; -Dimethylaminoethyl)-5-hydroxyindole;

3-(2-dimethylaminoethyl)-5-indolol;3-(2- dimethylaminoethyl)-5-indolol;

7-Ethyl-6,6β7-Ethyl-6,6β,7,8,9,10,12,13-octahydro-2-methoxy-6,9- ,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyridomethano-5H-pyrido [1', 2':1,2] azepino [5,4-b] indole;

3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran;

(V) Peyote, meaning all parts of the plant presently classified botanically as -Lophophora 36williamsii -Lemaire, 03-03whether 19:10growing 1stor Sub.not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));

(Green) S.B.

317 Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));

- 37 - SB0317 compared with SB0317S01 (BB) Ethylamine analog of phencyclidine, some trade or other names:

N-ethyl-1-phenylcyclohexylamine,N-ethyl-1- phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine, N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;

1-(1-phenylcyclohexyl)-pyrrolidine,1-(1-phenylcyclohexyl)- pyrrolidine, PCPy, PHP;

1-[1-(2-thienyl)-cyclohexyl]-piperidine,1-[1-(2-thienyl)-cyclohexyl]- piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP;

-(A) 37Mecloqualone; - 1st Sub.

(Green) S.B.

317 03-03 19:10 (A) Mecloqualone;

or 4,5-dihydro-5-phenyl-2-oxazolamine;4,5-dihydro-5- phenyl-2-oxazolamine;

alpha-(methylamino)propiophenone;alpha- (methylamino)propiophenone;

alpha-N-methylaminopropiophenone;alpha-N- methylaminopropiophenone;

N,N-alpha-trimethylphenethylamine.N,N-alpha- trimethylphenethylamine.

- 38 - SB0317 compared with SB0317S01 (vi) Any material, compound, mixture, or preparation which contains any quantity of the following substances, including their optical isomers, salts, and salts of isomers, subject to temporary emergency scheduling:

(A) Opium and opiate, and any salt, compound, derivative, or preparation of -opium 38or -opiate, 03-03excluding 19:10apomorphine, 1stdextrorphan, Sub.nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including:

(Green) S.B.

317 opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including:

and - 39 - SB0317 compared with SB0317S01 (XVI) Thebaine;

(ii) Unless specifically excepted or unless listed in another schedule, any of the -following 39[opiates] -substances, 1stincluding Sub.their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation, except dextrorphan and levopropoxyphene:

(Green) S.B.

317 03-03 19:10 following [opiates] substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation, except dextrorphan and levopropoxyphene:

- 40 - SB0317 compared with SB0317S01 (N) Metazocine;

(iii) Unless specifically excepted or unless listed in another schedule, any material, -compound, 40mixture, -or 03-03preparation 19:10which 1stcontains Sub.any quantity of the following substances having a stimulant effect on the central nervous system:

(Green) S.B.

317 compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:

1-phenylcyclohexylamine and 1-piperidinocyclohexanecarbonitrile1- piperidinocyclohexanecarbonitrile (PCC);

and - 41 - SB0317 compared with SB0317S01 (F) Secobarbital.

(v)(A)(v) (A) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of Phenylacetone.

(±(±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a- )-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,hexahydro-1-hydroxy-6, 6-dimethyl-9H-dibenzo[b,d]pyran-9-one.

(i) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its -salts, 41isomers -whether 1stoptical, Sub.position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:

(Green) S.B.

317 03-03 19:10 salts, isomers whether optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:

- 42 - SB0317 compared with SB0317S01 (A) Any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients which are not listed in any schedule;

± -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;-2-(2- chlorophenyl)-2-(methylamino)-cyclohexanone;

-(K) 42Sulfondiethylmethane; - 03-03 19:10 1st Sub.

(Green) S.B.

317 (K) Sulfondiethylmethane;

and (N) Tiletamine and zolazepam or any of their salts, some trade or other names for a tiletamine-zolazepamtiletamine- zolazepam combination product:

2-(ethylamino)-2-(2-thienyl)-cyclohexanone,2- (ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam:

4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e]4-(2- fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one, flupyrazapon.

(6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol,(6aR- trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or (-)-delta-9-(trans)-tetrahydrocannabinol.(-)-delta-9- (trans)-tetrahydrocannabinol.

- 43 - SB0317 compared with SB0317S01 (v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:

-(F) 43Not -more 1stthan Sub.300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;

(Green)(G) S.B.Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;

317 03-03 19:10 (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;

(G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;

- 44 - SB0317 compared with SB0317S01 (H) Fluoxymesterone;

-(W) 44Stanolone; - 03-03 19:10 1st Sub.

(Green) S.B.

317 (W) Stanolone;

- 45 - SB0317 compared with SB0317S01 (i) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them.

-(L) 45Clorazepate; - 1st Sub.

(Green) S.B.

317 03-03 19:10 (L) Clorazepate;

- 46 - SB0317 compared with SB0317S01 (Y) Halazepam;

-(TT) 46Pinazepam; - 03-03 19:10 1st Sub.

(Green) S.B.

317 (TT) Pinazepam;

- 47 - SB0317 compared with SB0317S01 (iii) Any material, compound, mixture, or preparation of fenfluramine which contains any quantity of the following substances, including its salts, isomers whether optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible.

(v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of dextropropoxyphene (alpha-(+)-4-dimethylamino-1, -2-diphenyl-3-methyl-2-propionoxybutane), 47including -its 1stsalts. Sub.

(Green) S.B.

317 03-03 19:10 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.

(i) Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the - 48 - SB0317 compared with SB0317S01 compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

58-37-658-37-6. (Effective 05/06/26) (Partially Repealed 07/01/32).

-(1) 48(a) -The 03-03division 19:10may 1stadopt Sub.rules relating to the licensing and control of the manufacture, distribution, production, prescription, administration, dispensing, conducting of research with, and performing of laboratory analysis upon controlled substances within this state.

(Green) S.B.

317 (1)(a) The division may adopt rules relating to the licensing and control of the manufacture, distribution, production, prescription, administration, dispensing, conducting of research with, and performing of laboratory analysis upon controlled substances within this state.

(2)(a)(i)(2) (a) - 49 - SB0317 compared with SB0317S01 (i) Every person who manufactures, produces, distributes, prescribes, dispenses, administers, conducts research with, or performs laboratory analysis upon any controlled substance in Schedules I through V within this state, or who proposes to engage in manufacturing, producing, distributing, prescribing, dispensing, administering, conducting research with, or performing laboratory analysis upon controlled substances included in Schedules I through V within this state shall obtain a license issued by the division.

(ii) a motor carrier or warehouseman, or an employee of a motor carrier or warehouseman, who possesses a controlled substance in the usual course of the -person's 49business -or 1stemployment; Sub.

(Green) S.B.

317 03-03 19:10 person's business or employment;

- 50 - SB0317 compared with SB0317S01 (e) A separate license is required at each principal place of business or professional practice where the applicant manufactures, produces, distributes, dispenses, conducts research with, or performs laboratory analysis upon controlled substances.

(3)(a)(i)(3) (a) (i) Upon proper application, the division shall license a qualified applicant to manufacture, produce, distribute, conduct research with, or perform laboratory analysis upon controlled substances included in Schedules I through V, unless it determines that issuance of a license is inconsistent with the public interest.

(c)(i)(c) - 51 - SB0317 compared with SB0317S01 (i) Practitioners shall be licensed to administer, dispense, or conduct research with -substances 50in -Schedules 03-03II 19:10through 1stV Sub.if they are authorized to administer, dispense, or conduct research under the laws of this state.

(Green) S.B.

317 substances in Schedules II through V if they are authorized to administer, dispense, or conduct research under the laws of this state.

(4)(a)(4) (a) Any license issued [pursuant to] in accordance with Subsection (2) or (3) may be denied, suspended, placed on probation, or revoked by the division upon finding that the applicant or licensee has:

- 52 - SB0317 compared with SB0317S01 (iv) had a federal registration or license denied, suspended, or revoked by competent federal authority and is no longer authorized to manufacture, distribute, prescribe, -or 51dispense -controlled 1stsubstances; Sub.

(Green) S.B.

317 03-03 19:10 or dispense controlled substances;

(c)(i)(c) (i) Proceedings to deny, revoke, or suspend a license shall be conducted [pursuant to] in accordance with this section and in accordance with the procedures set forth in Title 58, Chapter 1, Division of Professional Licensing Act, and conducted in conjunction with the appropriate representative committee designated by the director of the department.

(d)(i)(d) (i) The division may suspend any license simultaneously with the institution of proceedings under this section if it finds there is an imminent danger to the public health or safety.

(e)(i)- 53 - SB0317 compared with SB0317S01 (e) (i) If a license is suspended or revoked under this Subsection (4), all controlled substances owned or possessed by the licensee may be placed under seal in the -discretion 52of -the 03-03division. 19:10 1st Sub.

(Green) S.B.

317 discretion of the division.

(5)(a)(5) (a) A person licensed under Subsection (2) or (3) shall maintain records and inventories in conformance with the record keeping and inventory requirements of federal and state law and any additional rules issued by the division.

(b)(i)(b) (i) A physician, dentist, naturopathic physician, veterinarian, practitioner, or other individual who is authorized to administer or professionally use a controlled substance shall keep a record of the drugs received by the individual and a record of all drugs administered, dispensed, or professionally used by the individual otherwise than by a prescription.

(7)(a)(7) - 54 - SB0317 compared with SB0317S01 (a) An individual may not write or authorize a prescription for a controlled substance unless the individual is:

(i) a practitioner authorized to prescribe drugs and medicine under the laws of this -state 53or -under 1stthe Sub.laws of another state having similar standards;

(Green) S.B.

317 03-03 19:10 state or under the laws of another state having similar standards;

(c)(i)(c) (i) A controlled substance may not be dispensed without the written prescription of a practitioner, if the written prescription is required by the federal Controlled Substances Act.

- 55 - SB0317 compared with SB0317S01 (i) A prescription for a Schedule II substance may not be refilled.

-(ii) 54A -Schedule 03-03II 19:10controlled 1stsubstance Sub.may not be filled in a quantity to exceed a one-month's supply, as directed on the daily dosage rate of the prescriptions.

(Green)(iii) S.B.(A) A prescription for a Schedule II or Schedule III controlled substance that is an [opiate] opioid-like substance and that is issued for an acute condition shall be completely or partially filled in a quantity not to exceed a seven-day supply as directed on the daily dosage rate of the prescription.

317 (ii) A Schedule II controlled substance may not be filled in a quantity to exceed a one-month's supply, as directed on the daily dosage rate of the prescriptions.

(iii)(A) A prescription for a Schedule II or Schedule III controlled substance that is an [opiate] opioid-like substance and that is issued for an acute condition shall be completely or partially filled in a quantity not to exceed a seven-day supply as directed on the daily dosage rate of the prescription.

(C) A pharmacist is not required to verify that a prescription is in compliance with this Subsection (7)(f)(iii).(7)(f) (iii).

- 56 - SB0317 compared with SB0317S01 (i) issued or made by a prescribing practitioner who holds an unrestricted registration with the [federal] United States Drug Enforcement Administration, and an active -Utah 55controlled -substance 1stlicense Sub.in good standing issued by the division under this section, or a medical resident who is exempted from licensure under Subsection 58-1-307(1)(c);

(Green) S.B.

317 03-03 19:10 Utah controlled substance license in good standing issued by the division under this section, or a medical resident who is exempted from licensure under Subsection 58-1-307(1)(c);

(m) A person licensed under this chapter may not refuse or fail to make, keep, or furnish -any 56record -notification, 03-03order 19:10form, 1ststatement, Sub.invoice, or information required under this chapter.

(Green)- S.B.57 - SB0317 compared with SB0317S01 (n) A person licensed under this chapter may not refuse entry into any premises for inspection as authorized by this chapter.

317 any record notification, order form, statement, invoice, or information required under this chapter.

(n) A person licensed under this chapter may not refuse entry into any premises for inspection as authorized by this chapter.

(8)(a)(i)(8) (a) (i) Any person licensed under this chapter who is found by the division to have violated any of the provisions of Subsections (7)(k) through (o) or Subsection (10) is subject to a penalty not to exceed $5,000.

(9) Any information communicated to any licensed practitioner in an attempt to unlawfully procure, or to procure the administration of, a controlled substance is not considered to -be 57a -privileged 1stcommunication. Sub.

(Green)- S.B.58 - SB0317 compared with SB0317S01 (10) A person holding a valid license under this chapter who is engaged in medical research may produce, possess, administer, prescribe, or dispense a controlled substance for research purposes as licensed under Subsection (2) but may not otherwise prescribe or dispense a controlled substance listed in Section 58-37-4.2.

317(11) 03-03(a) 19:10As beused ain privilegedthis communication.Subsection (11):

(10) A person holding a valid license under this chapter who is engaged in medical research may produce, possess, administer, prescribe, or dispense a controlled substance for research purposes as licensed under Subsection (2) but may not otherwise prescribe or dispense a controlled substance listed in Section 58-37-4.2.

(11)(a) As used in this Subsection (11):

58-37-758-37-7. (Effective 05/06/26).

Labeling and packaging controlled substance -- Informational pamphlet for opioid-likeopioid- like substances -- Naloxone education and offer to dispense.

- 5859 - 03-03SB0317 19:10compared 1stwith Sub.SB0317S01 (2) No person except a pharmacist for the purpose of filling a prescription shall alter, deface, or remove any label affixed by the manufacturer.

(Green) S.B.

317 (2) No person except a pharmacist for the purpose of filling a prescription shall alter, deface, or remove any label affixed by the manufacturer.

or - 60 - SB0317 compared with SB0317S01 (C) is being dispensed a benzodiazepine and the pharmacy dispensed an [opioid] opioid-like substance to the patient in the previous 30 day period.

-(5) 59(a) -A 1stpharmacy Sub.who sells or dispenses a Schedule II or Schedule III controlled substance that is an [opiate] opioid-like substance shall, if available from the Department of Health and Human Services, prominently display at the point of sale the informational pamphlet developed by the Department of Health and Human Services under Section 26B-4-514.

(Green) S.B.

317 03-03 19:10 (5)(a) A pharmacy who sells or dispenses a Schedule II or Schedule III controlled substance that is an [opiate] opioid-like substance shall, if available from the Department of Health and Human Services, prominently display at the point of sale the informational pamphlet developed by the Department of Health and Human Services under Section 26B-4-514.

(7)(a)(7) (a) An individual to whom or for whose use any controlled substance has been prescribed, sold, or dispensed by a practitioner and the owner of any animal for which any controlled substance has been prescribed, sold, or dispensed by a veterinarian may lawfully possess it only in the container in which it was delivered to the individual by the person selling or dispensing it.

58-37-8.258-37-8.2. (Effective 05/06/26).

- 61 - SB0317 compared with SB0317S01 (e) "Practitioner" means an individual:

(i) licensed, registered, or otherwise authorized by the appropriate jurisdiction to administer, dispense, distribute, or prescribe a drug in the course of professional -practice; 60 - 03-03 19:10 1st Sub.

(Green) S.B.

317 practice;

58-37-1958-37-19. (Effective 05/06/26).

or (ii) was previously issued a prescription for an [opiate] opioid-like substance, but the date on which the current prescription is being issued is more than one year after the date on which an [opiate] opioid-likeopioid- like substance was previously prescribed or administered to the patient.

- 62 - SB0317 compared with SB0317S01 (b) the dangers of taking [opiates] opioid-like substances with alcohol, benzodiazepines, -and 61other -central 1stnervous Sub.system depressants;

(Green) S.B.

317 03-03 19:10 and other central nervous system depressants;

(4)(a)(4) (a) Beginning January 1, 2024, a prescriber shall offer to prescribe or dispense an [[opiate] opiate] opioid antagonist to a patient if the patient receives an initial [opiate] opioid-like substance prescription for:

The following section is affected by a coordination clause at the end of this bill.

58-67-70258-67-702. (Effective 05/06/26).

-(d) 62"[Opiate-related] -Opioid-related 03-03drug 19:10overdose 1stevent" Sub.means the same as that term is defined in Section 26B-4-501.

(Green) S.B.

317 (d) "[Opiate-related] Opioid-related drug overdose event" means the same as that term is defined in Section 26B-4-501.

- 63 - SB0317 compared with SB0317S01 (2) The prescribing or dispensing of an [opiate] opioid antagonist by a licensee under this chapter is not unprofessional or unlawful conduct if the licensee prescribed or dispensed the [opiate] opioid antagonist:

The following section is affected by a coordination clause at the end of this bill.

58-68-70258-68-702. (Effective 05/06/26).

-(i) 63an -individual 1stwho Sub.is at increased risk of experiencing an [opiate-related] opioid-related drug overdose event;

(Green) S.B.

317 03-03 19:10 (i) an individual who is at increased risk of experiencing an [opiate-related] opioid-related drug overdose event;

or - 64 - SB0317 compared with SB0317S01 (b) to an overdose outreach provider [pursuant to] in accordance with Subsection 26B-4-509(2)(a)(iii).

The following section is affected by a coordination clause at the end of this bill.

58-69-70258-69-702. (Effective 05/06/26).

or (b) to an overdose outreach provider [pursuant to] in accordance with Subsection -26B-4-509(2)(a)(iii). 64 - 03-03 19:10 1st Sub.

(Green) S.B.

317 26B-4-509(2)(a)(iii).

The following section is affected by a coordination clause at the end of this bill.

58-70a-50558-70a-505. (Effective 05/06/26).

- 65 - SB0317 compared with SB0317S01 (c) "[Opiate] Opioid antagonist" means the same as that term is defined in Section 26B-4-501.

63I-1-25863I-1-258. (Effective 05/06/26).

(1) Title 58, Chapter 13, Health Care Providers Immunity from Liability Act, is repealed -July 651, -2026. 1st Sub.

(Green) S.B.

317 03-03 19:10 July 1, 2026.

- 66 - SB0317 compared with SB0317S01 (11) Subsection 58-47b-102(9), defining massage assistant-in-training, is repealed July 1, 2029.

63J-1-602.263J-1-602.2. (Effective 05/06/26) (Partially Repealed 07/01/29).

-(5) 66The -LeRay 03-03McAllister 19:10Working 1stFarm Sub.and Ranch Fund Program created in Title 4, Chapter 46, Part 3, LeRay McAllister Working Farm and Ranch Fund.

(Green) S.B.

317 (5) The LeRay McAllister Working Farm and Ranch Fund Program created in Title 4, Chapter 46, Part 3, LeRay McAllister Working Farm and Ranch Fund.

and - 67 - SB0317 compared with SB0317S01 (c) provision of the forensic psychiatric fellowship grant described in Section 26B-4-712.

(25) The Division of Fleet Operations for the purpose of upgrading underground storage -tanks 67under -Section 1st63A-9-401. Sub.

(Green) S.B.

317 03-03 19:10 tanks under Section 63A-9-401.

- 68 - SB0317 compared with SB0317S01 (34) Programs for the Jordan River Recreation Area as described in Section 65A-2-8.

-(45) 68The -program 03-03established 19:10by 1stthe Sub.Division of Facilities Construction and Management under Section 63A-5b-703 under which state agencies receive an appropriation and pay lease payments for the use and occupancy of buildings owned by the Division of Facilities Construction and Management.

(Green) S.B.

317 (45) The program established by the Division of Facilities Construction and Management under Section 63A-5b-703 under which state agencies receive an appropriation and pay lease payments for the use and occupancy of buildings owned by the Division of Facilities Construction and Management.

64-13-4564-13-45. (Effective 05/06/26).

(b)(i)(b) (i) "In-custody death" means an inmate death that occurs while the inmate is in the custody of the department.

- 69 - SB0317 compared with SB0317S01 (c) "Inmate" means an individual who is processed or booked into custody or housed in the department or a correctional facility other than a county jail.

(2) The department shall submit a report to thethe{ State} Commission on Criminal and Juvenile Justice created in Section 63M-7-201 before June 15 of each year that includes:

(i) the known, or discoverable on reasonable inquiry, causes and contributing factors of each of the in-custodyin- custody deaths described in this Subsection (2)(a);

(ii) that relate to the department's provision, or lack of provision, of medications used -to 69treat, -mitigate, 1stor Sub.address an inmate's symptoms of withdrawal, including methadone and all forms of buprenorphine and naltrexone;

(Green) S.B.

317 03-03 19:10 to treat, mitigate, or address an inmate's symptoms of withdrawal, including methadone and all forms of buprenorphine and naltrexone;

- 70 - SB0317 compared with SB0317S01 (i) assigned to a living area with inmates whose biological sex at birth do not correspond with the transgender inmate's biological sex at birth;

(3) TheThe{ State} Commission on Criminal and Juvenile Justice shall:

(4) TheThe{ State} Commission on Criminal and Juvenile Justice may not provide access to or use the department's policies, procedures, or protocols submitted under this section in a manner or for a purpose not described in this section.

-Section 7030. - 03-03 19:10 1st Sub.

(Green)Effective S.B.date.

317 Section 30.

- 71 - SB0317 compared with SB0317S01 (3) Subsections 26B-4-511(1) and (2);

3-2-26 10:01 AM - 7172 -